Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03828A101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 4
|
0% |
8/14/2026
Event 6/30/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||
| VHCP Co-Investment Holdings III, LLC | 0% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||
| VHCP Management III, LLC | 0% | ||
| VHCP Management EG, LLC | 0% | ||
| Nimish Shah | 0% | ||
| Bong Y. Koh | 0% | ||
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Vestal Point Capital, LP | 0% | ||
| Ryan Wilder | 0% | ||
|
Propel Bio Management, LLC
13G/A
Amendment 2
|
4.2% |
12/31/2025
Event 12/29/2025
|
|
| Propel Bio Management, LLC | 4.2% | ||
| Leen Kawas | 4.2% | ||
| Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999 | 0% | ||
| Richard Kayne | 4.2% | ||
| Propel Bio Partners LLC | 4.2% | ||
|
Alexandria Real Estate Equities, Inc.
13G/A
Amendment 7
|
4.3% |
12/15/2025
Event 12/11/2025
|
|
| Alexandria Real Estate Equities, Inc. | 4.3% | ||
| Alexandria Venture Investments, LLC | 3.0% | ||
| Alexandria Equities No. 7, LLC | 1.4% | ||
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 3 | 14.9% |
11/14/2025
Event 9/30/2025
|
|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 2 | 13.2% |
8/14/2025
Event 6/30/2025
|
|
| Vanguard Group Inc 13G/A Amendment 1 | 3.3% |
7/29/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 2 | 3.7% |
7/16/2025
Event 6/30/2025
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 4
|
4.1% |
5/15/2025
Event 3/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 4.1% | ||
| VHCP Co-Investment Holdings III, LLC | 4.1% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 4.1% | ||
| VHCP Management III, LLC | 4.1% | ||
| VHCP Management EG, LLC | 4.1% | ||
| Nimish Shah | 4.1% | ||
| Bong Y Koh | 4.1% | ||
| Schonfeld Strategic Advisors LLC 13G/A Amendment 1 | 3.3% |
5/15/2025
Event 3/31/2025
|
|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 | 11.0% |
5/7/2025
Event 4/30/2025
|
|
| T. Rowe Price Investment Management, Inc. 13G | 8.9% |
5/7/2025
Event 3/31/2025
|
|
| Vanguard Group Inc 13G | 5.1% |
4/30/2025
Event 3/31/2025
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y Koh | 9.9% | ||
| Janus Henderson Group PLC 13G/A Amendment 3 | 0% |
2/14/2025
Event 12/31/2024
|
|
| Schonfeld Strategic Advisors LLC 13G | 7.5% |
2/14/2025
Event 12/31/2024
|
|
|
Alyeska Investment Group, L.P.
13G
|
5.8% |
2/14/2025
Event 12/31/2024
|
|
| Alyeska Investment Group, L.P. | 5.8% | ||
| Alyeska Fund GP, LLC | 5.8% | ||
| Anand Parekh | 5.8% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 3
|
2.4% |
2/14/2025
Event 12/31/2024
|
|
| Perceptive Advisors LLC | 2.4% | ||
| Joseph Edelman | 2.4% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 2.4% | ||
|
Vestal Point Capital, LP
13G
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Vestal Point Capital, LP | 9.9% | ||
| Ryan Wilder | 9.9% | ||
|
Morgan Stanley
13G/A
Amendment 2
|
2.5% |
2/7/2025
Event 1/31/2025
|
|
| Morgan Stanley | 2.5% | ||
| Morgan Stanley Capital Services LLC | 2.3% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 8.0% |
2/5/2025
Event 12/31/2024
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
10.1% |
2/3/2025
Event 1/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 10.1% | ||
| VHCP Co-Investment Holdings III, LLC | 10.1% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 10.1% | ||
| VHCP Management III, LLC | 10.1% | ||
| VHCP Management EG, LLC | 10.1% | ||
| Nimish Shah | 10.1% | ||
| Bong Y Koh | 10.1% | ||
|
Morgan Stanley
13G/A
Amendment 1
|
7.6% |
2/3/2025
Event 12/31/2024
|
|
| Morgan Stanley | 7.6% | ||
| Morgan Stanley Capital Services LLC | 7.3% | ||
|
Franklin Resources, Inc.
13G/A
Amendment 6
|
1.7% |
1/27/2025
Event 12/31/2024
|
|
| Franklin Resources, Inc. | 1.7% | ||
| Charles B. Johnson | 0% | ||
| Rupert H. Johnson, Jr. | 0% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 2
|
10.4% |
12/6/2024
Event 11/29/2024
|
|
| Janus Henderson Group PLC | 10.4% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 5.3% | ||
|
Franklin Resources, Inc.
13G/A
Amendment 5
|
5.9% |
10/31/2024
Event 9/30/2024
|
|
| Franklin Resources, Inc. | 5.9% | ||
| Charles B. Johnson | 0% | ||
| Rupert H. Johnson, Jr. | 0% | ||
| Franklin Advisers, Inc. | 5.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 57 | 67.2 M | $6.76 M |
| 2025 Q3 | 80 | 94.8 M | $57.2 M |
| 2025 Q2 | 82 | 88.1 M | $27.4 M |
| 2025 Q1 | 96 | 106 M | $51.9 M |
| 2024 Q4 | 133 | 115 M | $98.5 M |
| 2024 Q3 | 146 | 113 M | $961 M |
| 2024 Q2 | 107 | 107 M | $501 M |
| 2024 Q1 | 104 | 101 M | $683 M |
| 2023 Q4 | 96 | 61.6 M | $206 M |
| 2023 Q3 | 60 | 43.0 M | $107 M |
| 2023 Q2 | 45 | 31.5 M | $40.3 M |
| 2023 Q1 | 38 | 19.3 M | $15.6 M |
| 2022 Q4 | 42 | 19.8 M | $15.1 M |
| 2022 Q3 | 48 | 22.7 M | $21.1 M |
| 2022 Q2 | 56 | 26.7 M | $25.6 M |
| 2022 Q1 | 73 | 12.4 M | $26.0 M |
| 2021 Q4 | 77 | 15.0 M | $134 M |
| 2021 Q3 | 74 | 15.1 M | $251 M |
| 2021 Q2 | 72 | 15.4 M | $319 M |
| 2021 Q1 | 69 | 14.9 M | $279 M |
| 2020 Q4 | 75 | 12.1 M | $267 M |
| 2020 Q3 | 69 | 12.2 M | $253 M |
| 2020 Q2 | 74 | 11.8 M | $422 M |
| 2020 Q1 | 66 | 9.65 M | $315 M |
| 2019 Q4 | 47 | 5.06 M | $138 M |
| 2019 Q3 | 31 | 2.40 M | $26.3 M |
| 2019 Q2 | 14 | 2.20 M | $18.1 M |